|
|
|
03 Jul 2008 |
SkyePharma Announces Third Flutiform(TM) Phase III Efficacy Study Meets Primary Endpoints and Completes Original Core Clinical Trial Programme
|
|
03 Jul 2008 |
ARYx Therapeutics, Inc. Announces Successful Results of QT Study on ATI-7505
|
|
03 Jul 2008 |
Evotec's EVT 101 Well Tolerated in Four Week Higher Repeat Dose Safety Study
|
|
03 Jul 2008 |
Adolor Provides Update on Entereg(R) (alvimopan) OBD Program
|
|
03 Jul 2008 |
ARYx Therapeutics, Inc. Announces Procter & Gamble Exercises Option to End Collaboration on ATI-7505
|
|
03 Jul 2008 |
Wyeth and Progenics Receive Approval from European Commission for RELISTOR for Opioid-Induced Constipation in Advanced Illness Patients
|
|
01 Jul 2008 |
Sciele Pharma Signs Agreement with Addrenex Pharmaceuticals To Develop and Market ADX415 for the Treatment of Hypertension
|
|
01 Jul 2008 |
Palatin Technologies Announces Amendment Expanding AstraZeneca Obesity Collaboration
|
|
01 Jul 2008 |
EPIX Pharmaceuticals Announces Resubmission of New Drug Application for Vasovist(R)
|
|
01 Jul 2008 |
SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
|
|
01 Jul 2008 |
SCOLR Pharma, Inc. Advances Extended-Release Ibuprofen with Initiation of Clinical Study
|
|
01 Jul 2008 |
Salix Initiates Phase 3 for Rifaximin in Non–Constipation Irritable Bowel Syndrome
|
|
01 Jul 2008 |
Ore Pharmaceuticals Files Investigational New Drug Application with FDA
|
|
01 Jul 2008 |
Proton Pump Inhibitor ACIPHEX(R) 20 mg Receives Approvalfor Short-Term Treatment of GERD in Adolescents in United States
|
|
30 Jun 2008 |
Aradigm Reports Successful Top-line Phase 2 Data with Inhaled Liposomal Ciprofloxacin for Cystic Fibrosis
|
|
30 Jun 2008 |
New Drug Application for Inhaled Treprostinil Submitted to the U.S. Food and Drug Administration
|
|
30 Jun 2008 |
Ceftobiprole, a new anti-MRSA broad-spectrum antibiotic, receives its first marketing authorization by Health Canada
|
|
30 Jun 2008 |
Indevus Receives Approvable Letter from FDA for NEBIDO(R)
|
|
30 Jun 2008 |
DG041 Blocks Platelet Aggregation Through a Novel Mechanism and does not Increase Bleeding Time When Given Alone or With Plavix(TM) or Aspirin
|
|
30 Jun 2008 |
Data Presented at American Headache Society’s Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics’ Tezampanel
|
|
30 Jun 2008 |
Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
|
|
30 Jun 2008 |
SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393
|
|
30 Jun 2008 |
Repros Therapeutics Inc. Initiates a Comparative Phase 2b Study of Oral Androxal(R) as Compared to Topical Testim(R) Examining Effects on Male Fertility and Testicular Function
|
|
30 Jun 2008 |
Rivaroxaban is First Novel Oral Anticoagulant to Significantly Reduce the Composite Outcome of Symptomatic VTE and Death
|
|
30 Jun 2008 |
NuPathe Reports Positive Phase I Results for NP101, a Novel Transdermal Patch for Acute Migraine
|
|
30 Jun 2008 |
Labopharm Receives Response from FDA Regarding its Once-Daily Tramadol Product
|
|
30 Jun 2008 |
Headline results of Flurizan(R) in clinical phase III trial
|
|
29 Jun 2008 |
UCB's Vimpat(TM) recommended for approval in Europe for epilepsy
|
|
29 Jun 2008 |
Schering-Plough and Merck Announce Withdrawal of Loratadine/Montelukast NDA and Termination of Respiratory Joint Venture
|
|
29 Jun 2008 |
European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder
|
|
29 Jun 2008 |
Bosentan (Tracleer(R)) receives positive EU opinion for treatment of patients with mildly symptomatic WHO Functional Class II pulmonary arterial hypertension
|
|
29 Jun 2008 |
FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
|
|
29 Jun 2008 |
Merck's Investigational Migraine Treatment Telcagepant Improved Pain and Migraine-Associated Symptoms in Phase III Study
|
|
29 Jun 2008 |
iCo Therapeutics Reports New iCo-009 (Oral Amphotericin B) Preclinical Results
|
|
29 Jun 2008 |
Orexo report Abstral (Rapinyl) approval in Europe
|
|
29 Jun 2008 |
Liver Phase I Results Presented at WCIO 2008 & Best of ASCO(R)
|
|
29 Jun 2008 |
MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
|
|
29 Jun 2008 |
Optimer Reports Additional Data on Investigational Compound OPT-80 at Anaerobe 2008 Congress
|
|
26 Jun 2008 |
Alkermes Initiates Phase 3 Clinical Study of VIVITROL(R) for the Treatment of Opioid Dependence
|
|
26 Jun 2008 |
Avalon Pharmaceuticals Nominates Lead Clinical Development Candidate in its Beta-catenin Pathway Inhibitor Program
|
|
26 Jun 2008 |
Phase III Data Show Vanda Pharmaceuticals' Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
|
|
26 Jun 2008 |
NeuroSearch successfully completes Phase I with ACR325 and announces the decision to progress development into Phase II Proof-of-Concept studies in Parkinson’s disease and Bipolar Disorder
|
|
26 Jun 2008 |
U.S. Food and Drug Administration Advisory Committee Recommends Approval of Tolvaptan, an Investigational Treatment for Hyponatremia
|
|
25 Jun 2008 |
Promising Results for Oral CP-4126
|
|
25 Jun 2008 |
SurModics Announces Initiation by Merck & Co., Inc. of Phase IIb Clinical Trial for I-vation(TM) TA
|
|
25 Jun 2008 |
Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
|
|
25 Jun 2008 |
Lux Biosciences Completes Enrollment in LUMINATE Pivotal Trial Program for Novel Uveitis Therapy, LUVENIQ(TM)
|
|
25 Jun 2008 |
Mpex Initiates a Phase 2 Clinical Trial of Aerosol MP-376 in the Treatment of Chronic Bacterial Infections in Cystic Fibrosis Patients
|
|
25 Jun 2008 |
MethylGene Announces the Initiation of a Randomized, Three-Arm Phase II Trial of MGCD0103 in Combination With Vidaza® in Patients With High-Risk MDS or AML
|
|
24 Jun 2008 |
MediGene Achieves Positive Results with RhuDex(R) in Clinical Phase IIa Trial
|
| |
|
Results 1 - 50 of 5006 |
